321 related articles for article (PubMed ID: 11877472)
1. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
Karandikar NJ; Crawford MP; Yan X; Ratts RB; Brenchley JM; Ambrozak DR; Lovett-Racke AE; Frohman EM; Stastny P; Douek DC; Koup RA; Racke MK
J Clin Invest; 2002 Mar; 109(5):641-9. PubMed ID: 11877472
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis.
Tennakoon DK; Mehta RS; Ortega SB; Bhoj V; Racke MK; Karandikar NJ
J Immunol; 2006 Jun; 176(11):7119-29. PubMed ID: 16709875
[TBL] [Abstract][Full Text] [Related]
3. Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis.
Putheti P; Soderstrom M; Link H; Huang YM
J Neuroimmunol; 2003 Nov; 144(1-2):125-31. PubMed ID: 14597106
[TBL] [Abstract][Full Text] [Related]
4. Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis.
Biegler BW; Yan SX; Ortega SB; Tennakoon DK; Racke MK; Karandikar NJ
J Neuroimmunol; 2006 Nov; 180(1-2):159-71. PubMed ID: 16935352
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of TRAIL expression on human T lymphocytes by interferon beta and glatiramer acetate.
Arbour N; Rastikerdar E; McCrea E; Lapierre Y; Dörr J; Bar-Or A; Antel JP
Mult Scler; 2005 Dec; 11(6):652-7. PubMed ID: 16320724
[TBL] [Abstract][Full Text] [Related]
6. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study.
Blanco Y; Moral EA; Costa M; Gómez-Choco M; Torres-Peraza JF; Alonso-Magdalena L; Alberch J; Jaraquemada D; Arbizu T; Graus F; Saiz A
Neurosci Lett; 2006 Oct; 406(3):270-5. PubMed ID: 16934924
[TBL] [Abstract][Full Text] [Related]
7. CD28-CD57+ T cells predominate in CD8 responses to glatiramer acetate.
Ratts RB; Lovett-Racke AE; Choy J; Northrop SC; Hussain RZ; Karandikar NJ; Racke MK
J Neuroimmunol; 2006 Sep; 178(1-2):117-29. PubMed ID: 16837065
[TBL] [Abstract][Full Text] [Related]
8. Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing-remitting multiple sclerosis patients.
Berthelot L; Miqueu P; Pettré S; Guillet M; Moynard J; Wiertlewski S; Lefrère F; Brouard S; Soulillou JP; Laplaud DA
Clin Immunol; 2010 Apr; 135(1):33-42. PubMed ID: 20116333
[TBL] [Abstract][Full Text] [Related]
9. Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells.
Ragheb S; Abramczyk S; Lisak D; Lisak R
Mult Scler; 2001 Feb; 7(1):43-7. PubMed ID: 11321193
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis.
Sellebjerg F; Hesse D; Limborg S; Lund H; Søndergaard HB; Krakauer M; Sørensen PS
Mult Scler; 2013 Feb; 19(2):179-87. PubMed ID: 22653658
[TBL] [Abstract][Full Text] [Related]
11. Glatiramer acetate-specific human CD8(+) T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment.
Dressel A; Vogelgesang A; Brinkmeier H; Mäder M; Weber F
J Neuroimmunol; 2006 Dec; 181(1-2):133-40. PubMed ID: 17084909
[TBL] [Abstract][Full Text] [Related]
12. Induction of apoptosis of CD4+ T cells by immunomodulatory therapy of multiple sclerosis with glatiramer acetate.
Rieks M; Hoffmann V; Aktas O; Juschka M; Spitzer I; Brune N; Schimrigk S; Przuntek H; Pöhlau D
Eur Neurol; 2003; 50(4):200-6. PubMed ID: 14634263
[TBL] [Abstract][Full Text] [Related]
13. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
Duda PW; Schmied MC; Cook SL; Krieger JI; Hafler DA
J Clin Invest; 2000 Apr; 105(7):967-76. PubMed ID: 10749576
[TBL] [Abstract][Full Text] [Related]
14. Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells.
Farina C; Then Bergh F; Albrecht H; Meinl E; Yassouridis A; Neuhaus O; Hohlfeld R
Brain; 2001 Apr; 124(Pt 4):705-19. PubMed ID: 11287371
[TBL] [Abstract][Full Text] [Related]
15. CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
Tyler AF; Mendoza JP; Firan M; Karandikar NJ
PLoS One; 2013; 8(6):e66772. PubMed ID: 23805274
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of naive Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis.
Kantengwa S; Weber MS; Juillard C; Benkhoucha M; Fellay B; Zamvil SS; Gougeon ML; Chofflon M; Lalive PH
J Neuroimmunol; 2007 Apr; 185(1-2):123-9. PubMed ID: 17306890
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis.
Horani A; Muhanna N; Pappo O; Melhem A; Alvarez CE; Doron S; Wehbi W; Dimitrios K; Friedman SL; Safadi R
Am J Physiol Gastrointest Liver Physiol; 2007 Feb; 292(2):G628-38. PubMed ID: 17038628
[TBL] [Abstract][Full Text] [Related]
18. Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis.
Zafranskaya M; Oschmann P; Engel R; Weishaupt A; van Noort JM; Jomaa H; Eberl M
Immunology; 2007 May; 121(1):29-39. PubMed ID: 17239199
[TBL] [Abstract][Full Text] [Related]
19. Characterization of CD8+ T cell repertoire in identical twins discordant and concordant for multiple sclerosis.
Somma P; Ristori G; Battistini L; Cannoni S; Borsellino G; Diamantini A; Salvetti M; Sorrentino R; Fiorillo MT
J Leukoc Biol; 2007 Mar; 81(3):696-710. PubMed ID: 17110420
[TBL] [Abstract][Full Text] [Related]
20. HLA-E restricted CD8+ T cell subsets are phenotypically altered in multiple sclerosis patients.
Pannemans K; Broux B; Goris A; Dubois B; Broekmans T; Van Wijmeersch B; Geraghty D; Stinissen P; Hellings N
Mult Scler; 2014 Jun; 20(7):790-801. PubMed ID: 24144875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
